检索结果-南通市图书馆

金属螯合物印迹聚邻苯二胺膜的电化学合成及表征

在线全文

学校读者我要写书评

暂无评论

物理化学学报 2011年第6期27卷 1451-1456页

作者：汪莲艳陆枫吴福全顾仁敖姚建林张海禄邓宗武中国科学院苏州纳米技术与纳米仿生研究所江苏苏州215123 苏州大学材料与化学化工学部江苏苏州215123 苏州市环境监测中心站江苏苏州215004

以邻苯二胺(o-PD)为功能单体,乙二胺四乙酸铜离子螯合物(Cu(II)-EDTA)为模板分子,利用循环伏安法(CV)合成了Cu(II)-EDTA分子印迹聚合物(MIPs).通过紫外-可见(UV-Vis)光谱、X射线光电子能谱(XPS)、差分脉冲伏安法(DPV)、石英晶体微天平(Q... 详细信息

以邻苯二胺(o-PD)为功能单体,乙二胺四乙酸铜离子螯合物(Cu(II)-EDTA)为模板分子,利用循环伏安法(CV)合成了Cu(II)-EDTA分子印迹聚合物(MIPs).通过紫外-可见(UV-Vis)光谱、X射线光电子能谱(XPS)、差分脉冲伏安法(DPV)、石英晶体微天平(QCM)等手段对合成的聚合物进行了表征.UV-Vis光谱分析表明当溶液的pH≥5.0时有利于邻苯二胺电聚合形成聚合度较高的聚合物;XPS结果证明Cu(II)-EDTA螯合物被成功地包覆在聚合物膜中,且推断出模板分子和聚合物之间可能主要靠氢键相互作用;DPV实验结果证明模板分子能够被有效洗脱;QCM的测试结果表明此方法合成的Cu(II)-EDTA印迹聚合物膜对Cu(II)-EDTA具有良好的响应度.

关键词：邻苯二胺螯合物分子印迹聚合物循环伏安法石英晶体微天平

Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline(updated version)

在线全文

学校读者我要写书评

暂无评论

Military Medical Research 2020年第3期7卷 249-282页

作者： Ying-Hui Jin Qing-Yuan Zhan Zhi-Yong Peng Xue-Qun ren Xun-Tao Yin Lin Cai Yu-feng Yuan Ji-Rong Yue Xiao-Chun Zhang Qi-Wen Yang jianguang Ji jian Xia Yi-Rong Li Fu-Xiang Zhou Ya-Dong Gao Zhui Yu feng Xu Ming-Li Tu Li-Ming Tan Min Yang Fang Chen Xiao-Ju Zhang Mei Zeng Yu Zhu Xin-Can Liu jian Yang Dong-Chi Zhao Yu-feng Ding Ning Hou Fu-Bing Wang Hao Chen Yong-Gang Zhang Wei Li Wen Chen Yue-Xian Shi Xiu-Zhi Yang Xue-Jun Wang Yan-Jun Zhong Ming-Juan Zhao Bing-Hui Li Lin-lu Ma Hao Zi Na Wang Yun-Yun Wang Shao-Fu Yu lu-Yao Li Qiao Huang Hong Weng Xiang-Ying ren Li-Sha luo Man-Ru Fan Di Huang Hong-Yang Xue Lin-Xin Yu Jin-Ping Gao Tong deng Xian-Tao Zeng Hong-Jun Li Zhen-Shun Cheng Xiao-Mei Yao Xing-Huan Wang Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Respiratory Diseases China-Japan Friendship HospitalBeijing 100029China Department of Pulmonary and Critical Care Medicine China-Japan Friendship HospitalBeijing 10029China Leishenshan Hospital in Wuhan Wuhan 430200China Department of Critical Care Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Institutes of Evidence-based Medicine and Knowledge Translation Henan UniversityKaifeng 475000HenanChina Department of Medical Imaging Guizhou Provincial People’s HospitalGuiyang 550002China Departments of Orthopedics Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Radiology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Clinical Laboratory Peking Union Medical College Hospital(PUMCH)Peking Union Medical CollegeChinese Academy of Medical Sciences(CAMS)Beijing 100730China Center for Primary Health Care Research Lund University and Region Skåne25002 MalmöSweden Emergency Center Zhongnan Hospital of Wuhan UniversityWuhan 403371China Department of Allergology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan UniversityWuhan 43071China Department of Critical Care Medicine Renmin Hospital of Wuhan UniversityWuhan 430060China Department of Emergency Medicine and Chest Pain Center Qilu Hospital of Shandong UniversityJinan 250002China Department of Respiratory and Critical Care Medicine Suizhou Central HospitalHubei University of MedicineSuizhou 441300HubeiChina Department of Clinic Pharmacy Second People’s Hospital of Huaihua Ci

The novel severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the cause of a rapidly spreading illness,coronavirus disease 2019(COVID-19),affecting more than seventeen million people around the *** and treatment guidelines for clinicians caring for patients are *** the early stage,we have issued"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV)infected pneumonia(standard version)";now there are many direct evidences emerged and may change some of previous recommendations and it is ripe for develop an evidence-based *** formed a working group of clinical experts and *** steering group members proposed 29 questions that are relevant to the management of COVID-19 covering the following areas:chemoprophylaxis,diagnosis,treatments,and discharge *** searched the literature for direct evidence on the management of COVID-19,and assessed its certainty generated recommendations using the Grading of Recommendations,Assessment,Development and Evaluation(GRADE)*** were either strong or weak,or in the form of ungraded consensus-based ***,we issued 34 *** them,6 were strong recommendations for,14 were weak recommendations for,3 were weak recommendations against and 11 were ungraded consensus-based *** covered topics of chemoprophylaxis(including agents and Traditional Chinese Medicine(TCM)agents),diagnosis(including clinical manifestations,reverse transcription-polymerase chain reaction(RT-PCR),respiratory tract specimens,IgM and IgG antibody tests,chest computed tomography,chest X-ray,and CT features of asymptomatic infections),treatments(including lopinavirritonavir,umifenovir,favipiravir,interferon,remdesivir,combination of antiviral drugs,hydroxychloroquine/chloroquine,interleukin-6 inhibitors,interleukin-1 inhibitors,glucocorticoid,qingfei paidu decoction,lianhua qingwen granules/capsules,convalescent plasma,lung

关键词： COVID-19 SARS-CoV-2 Recommendation Chemoprophylaxis Diagnosis Treatment Discharge management Traditional Chinese medicine guideline

二苯基-(三甲基硅基亚甲基)锡化合物的合成、结构及杀螨活性

在线全文

学校读者我要写书评

暂无评论

南昌大学学报（理科版） 2011年第2期35卷 151-154页

作者：林森邹引波郑剑霞邓瑞红任华莉邓锋杰南昌大学化学系江西南昌330031

合成了二苯基-(三甲基硅基亚甲基)碘化锡及10个二苯基-(三甲基硅基亚甲基)锡芳香酸酯,并通过IR和1H NMR对目标化合物结构进行了表征,结果显示,二苯基-(三甲基硅基亚甲基)锡芳香酸酯为中心锡原子四配位的单体结构。生物活性实验的初步结... 详细信息

合成了二苯基-(三甲基硅基亚甲基)碘化锡及10个二苯基-(三甲基硅基亚甲基)锡芳香酸酯,并通过IR和1H NMR对目标化合物结构进行了表征,结果显示,二苯基-(三甲基硅基亚甲基)锡芳香酸酯为中心锡原子四配位的单体结构。生物活性实验的初步结果表明,该类化合物具有一定的杀螨活性。

关键词：混合三烃基锡化合物合成结构杀螨活性

The mini-GWAC optical follow-up of gravitational wave alerts – results from the O2 campaign and prospects for the upcoming O3 run

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2020年第1期20卷 107-123页

作者： Damien Turpin Chao Wu Xu-Hui Han Li-Ping Xin Sarah Antier Nicolas Leroy Li Cao Hong-Bo Cai Bertrand Cordier Jin-Song deng Wen-Long Dong Qi-Chen feng Lei Huang Lei Jia Alain Klotz Cyril Lachaud Hua-Li Li En-Wei Liang Shun-Fang Liu Xiao-Meng lu Xian-Min Meng Yu-Lei Qiu Hui-Juan Wang Jing Wang Shen Wang Xiang-Gao Wang jian-Yan Wei Bo-Bing Wu Yu-Jie Xiao Da-Wei Xu Yang Xu Yuan-Gui Yang Pin-Pin Zhang Ruo-Song Zhang Shuang-Nan Zhang Ya-Tong ZhengandSi-Cheng zou Key Laboratory of Space Astronomy and Technology National Astronomical ObservatoriesChinese Academy of SciencesBeijing 100101China LAL Univ.Paris-SudCNRS/IN2P3Universite Paris-SaclayF-91898 OrsayFrance APC Univ Paris DiderotCNRS/IN2P3CEA/lrfuObs de ParisSorbonne Paris CiteFrance CEA Saclay DRF/IRFU/Departement d’astrophysique91191 Gif-sur-YvetteFrance School of Astronomy and Space Science University of Chinese Academy of SciencesBeijing 101408China Universite de Toulouse IRAP 14 Av.Edouard BelinF-31000 ToulouseFrance Institut de Recherche en Astrophysique et Planetologie(IRAP) UPS-OMPToulouseFrance Guangxi Key Laboratory for Relativistic Astrophysics School of Physical Science and TechnologyGuangxi UniversityNanning 530004China Institute of High Energy Physics Chinese Academy of SciencesBeijing 100049China School of Physics and Electronic Information Huaibei Normal UniversityHuaibei 235000China

The second(O2)observational campaign of gravitational waves(GWs)organized by the LIGO/Virgo Collaborations has led to several breakthroughs such as the detection of GW signals from merger systems involving black holes or neutrons *** O2,14 GW alerts were sent to the astronomical community with sky regions mostly covering over hundreds of square *** them,six were finally confirmed as real astrophysical *** 2013,a new set of ground-based robotic telescopes called Ground-based Wide Angle Camera system(GWAC)project and its pathfinder mini-GWAC has been developed to contribute to the various challenges of multi-messenger and time domain *** GWAC system is built up in the framework of the ground-segment system of the SVOM mission that will be devoted to the study of the multi-wavelength transient sky in the next *** O2,only the mini-GWAC telescope network was fully *** to the wide field of view and fast automatic follow-up capabilities of the mini-GWAC telescopes,they were adept to efficiently cover the sky localization areas of GW event *** this paper,we present the mini-GWAC pipeline we have set up to respond to GW alerts and we report our optical follow-up observations of eight GW alerts detected during the O2 *** observations provided the largest coverage of the GW localization areas with a short latency made by any optical *** found tens of optical transient candidates in our images,but none of those could be securely associated with any confirmed black hole-black hole merger *** on this first experience and the near future technical improvements of our network system,we will be more competitive in detecting the optical counterparts from some GW events that will be identified during the upcoming O3 run,especially those emerging from binary neutron star mergers.

关键词： gravitational waves methods:data analysis methods:observational (stars:)gammaray burst:general

CEPC Technical Design Report

在线全文

学校读者我要写书评

暂无评论

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed Xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai Yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci Xiao-Jun Bi Yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai Wujun Cai Yijian Cai Yizhou Cai Yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi Junsong Cang Guofu Cao jianshe Cao Antoine Chance Xuejun Chang Yue Chang Zhe Chang Xinyuan Chang Wei Chao Auttakit Chatrabhuti Yimin Che Yuzhi Che Bin Chen Danping Chen Fuqing Chen Fusan Chen Gang Chen Guoming Chen Hua-Xing Chen Huirun Chen Jinhui Chen Ji-Yuan Chen Kai Chen Mali Chen Mingjun Chen Mingshui Chen Ning Chen Shanhong Chen Shanzhen Chen Shao-Long Chen Shaomin Chen Shiqiang Chen Tianlu Chen Wei Chen Xiang Chen Xiaoyu Chen Xin Chen Xun Chen Xurong Chen Ye Chen Ying Chen Yukai Chen Zelin Chen Zilin Chen Gang Chen Boping Chen Chunhui Chen Hok Chuen Cheng Huajie Cheng Shan Cheng Tongguang Cheng Yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho Ming-Chung Chu Xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui Xiaohao Cui Zhaoyuan Cui Brunella D'Anzi Ling-Yun Dai Xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue deng Wei-Tian deng Zhi deng Ziyan deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding Haiyi Dong jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central China Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa Chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan China academy of engineering physics MianyangSichuan China building materials academy Beijing China Center of Advanced Science and Technology Beijing China Institute of Atomic Energy Beijing China Jiliang University HangzhouZhejiang China Nuclear Instrument CO. LTDBeijing China University of Geosciences Beijing China University of Geosciences WuhanHubei China University of Mining and Technology XuzhouJiangsu China West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing Chulalongkorn University Bangkok City University of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East China University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by China,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV Linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The Linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV) infected pneumonia(standard version)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Military Medical Research 2020年第1期7卷 1-22页

作者： Ying-Hui Jin Lin Cai Zhen-Shun Cheng Hong Cheng Tong deng Yi-Pin Fan Cheng Fang Di Huang lu-Qi Huang Qiao Huang Yong Han Bo Hu Fen Hu Bing-Hui Li Yi-Rong Li Ke Liang Li-Kai Lin Li-Sha luo Jing Ma Lin-lu Ma Zhi-Yong Peng Yun-Bao Pan Zhen-Yu Pan Xue-Qun ren Hui-Min Sun Ying Wang Yun-Yun Wang Hong Weng Chao-Jie Wei Dong-Fang Wu jian Xia Yong Xiong Hai-Bo Xu Xiao-Mei Yao Yu-feng Yuan Tai-Sheng Ye Xiao-Chun Zhang Ying-Wen Zhang Yin-Gao Zhang Hua-Min Zhang Yan Zhao Ming-Juan Zhao Hao Zi Xian-Tao Zeng Yong-Yan Wang Xing-Huan Wang 无 Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Institute of Hospital Management Wuhan UniversityWuhan 430071China Department of Respiratory Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Pharmacy Zhongnan Hospital of Wuhan UniversityWuhan 430071China Institute of Evidence-Based Medicine and Knowledge Translation Henan UniversityKaifeng 475000China China Academy of Chinese Medical Sciences Beijing 100700China China Center for Evidence Based Traditional Chinese Medicine(CCEBTCM) Beijing 100700China Department of Critical Care Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Clinical Laboratory Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Infectious Diseases Zhongnan Hospital of Wuhan UniversityWuhan 430071China Division of Medical Affairs Zhongnan Hospital of Wuhan UniversityWuhan 430071China Division of Nursing Affairs Zhongnan Hospital of Wuhan UniversityWuhan 430071China Office of Nosocomial Infection Control Zhongnan Hospital of Wuhan UniversityWuhan 430071China Emergency Center Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Radiology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Health Research Methods Evidenceand ImpactMcMaster UniversityHamiltonON L8S 4L8Canada Department of Traditional Chinese Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Global Health Institute Wuhan UniversityWuhan 430072China the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care(CPAM)

In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province;and then named "2019 novel coronavirus(2019-nCoV)" by the World Health Organization(WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development;we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control(including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV.

关键词： 2019 novel coronavirus 2019-nCoV Respiratory disease Pneumonia Infectious diseases Rapid advice guideline Clinical practice guideline Evidence-based medicine

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

在线全文

学校读者我要写书评

暂无评论

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： Jie Wu Shu-wei Duan Hong-tao Yang Yue-yi deng Wei Li Ya-ni He Zhao-hui Ni Yong-li Zhan Shan Lin Zhi-yong Guo Jun Zhu Jing-ai Fang Xu-sheng Liu Li-hua Wang Rong Wang Nian-song Wang Xiao-hong Cheng Li-qun He Ping luo Shi-ren Sun Ji-feng Sun Ai-ping Yin Geng-ru jiang Hong-yu Chen Wen-hu Liu Hong-li Lin Meng Liang lu Ma Ming Chen Li-qun Song jian Chen Qing Zhu Chang-ying Xing Yun Li Ji-ning Gao Rong-shan Li Ying Li Hao Zhang Ying lu Qiao-ling Zhou Jun-zhou Fu Qiang He Guang-yan Cai Xiang-mei Chen Department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China Department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China Department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina Department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China Department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China Department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China Department of Nephrology Tianjin Medical University General HospitalTianjin 300052China Department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China Department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina Department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina Department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China Department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina Department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China Department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(Plus losartan potassium 100 mg group had a 9.77%±2.52%(P=0.001)greater reduction in urine *** a superiority threshold of 15%,neither was statistically ***,serum creatinine and serum albumin from the baseline did not change statistically *** average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any ***:SYKFT decreased the proteinur

关键词： Herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

在线全文

学校读者我要写书评

暂无评论

杨树无性系光合特征的研究

植物研究 2006年第5期26卷 600-608页

作者：邓松录狄晓艳王孟本陈建文张伟峰任建中周玉泉刘存平山西大学黄土高原研究所太原030006 山西省杨树丰产林实验局大同037006

对新培育的金科系列的4个杨树无性系（3^#、6^#、8^#、9^#）的光合特征及净光合速率、水分利用效率与主要影响因子的关系进行了研究。结果表明：不同月份4个无性系的净光合速率的日进程一般在10：00左右达到峰值，然后逐渐降低；蒸腾速... 详细信息

对新培育的金科系列的4个杨树无性系（3^#、6^#、8^#、9^#）的光合特征及净光合速率、水分利用效率与主要影响因子的关系进行了研究。结果表明：不同月份4个无性系的净光合速率的日进程一般在10：00左右达到峰值，然后逐渐降低；蒸腾速率日进程不尽一致；气孔导度在7：00～9：00出现峰值后。缓慢下降。在6～8月，4个无性系的净光合速率的总平均值（μmol CO2·m^-2·s^-1）排序为：无性系9^#（8．53）〉6^#〉（7．21）3^#（6．47）〉8^#（4．98）；蒸腾速率的总平均值（mmol H2O·m^-2·s^-1）排序为：无性系9^#（3．74）〉3^#（2．76）〉6^#（1．76）〉8^#（1．47）；水分利用效率的总平均值（mmol CO2·mol^-1H2O）排序为：无性系8^#（4．77）〉6^#（4．35）〉3^#（2．99）〉9^#（2．40）。4个无性系的净光合速率与水分利用效率的排序并不一致。9^#属于高光合、高蒸腾、低水分利用效率类型。8^#属低光合、低蒸腾、高水分利用效率类型。在6月份6^#无性系的净光合速率和水分利用效率与温度、湿度显著相关，3^#、8^#、9^#无性系与光合有效辐射和气孔导度密切相关。

关键词：净光合速率蒸腾速率光合有效辐射气孔导度水分利用效率

Prevalence and clinical characteristics of autoimmune liver disease in hospitalized patients with cirrhosis and acute decompensation in China

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2022年第31期28卷 4417-4430页

作者： Zi-Xuan Shen Dan-Dan Wu Jie Xia Xian-Bo Wang Xin Zheng Yan Huang Bei-Ling Li Zhong-Ji Meng Yan-Hang Gao Zhi-Ping Qian feng Liu Xiao-Bo lu Jia Shang Hua-Dong Yan Yu-Bao Zheng Wen-Yi Gu Yan Zhang jian-Yi Wei Wen-Ting Tan Yi-Xin Hou Qun Zhang Yan Xiong Cong-Cong zou Jun Chen Ze-Bing Huang Xiu-Hua jiang Sen luo Yuan-Yuan Chen Na Gao Chun-Yan Liu Wei Yuan Xue Mei Jing Li Tao Li Xin-Yi Zhou Guo-Hong deng Jin-Jun Chen Xiong Ma Hai Li Department of Gastroenterology Renji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200127China Shanghai Institute of Digestive Disease Key Laboratory of Gastroenterology and HepatologyChinese Ministry of HealthShanghai Jiao Tong UniversityShanghai 200001China Department of Infectious Diseases Southwest HospitalThe Third Military Medical University(Army Medical University)Chongqing 400038China Center of Integrative Medicine Beijing Ditan HospitalCapital Medical UniversityBeijing 100102China Department of Infectious Diseases Institute of Infection and ImmunologyUnion HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022Hubei ProvinceChina Department of Infectious Diseases Hunan Key Laboratory of Viral HepatitisXiangya HospitalCentral South UniversityChangsha 410008Hunan ProvinceChina Hepatology Unit Department of Infectious DiseasesNanfang HospitalSouthern Medical UniversityGuangzhou 510515Guangdong ProvinceChina Department of Infectious Disease Taihe HospitalHubei University of MedicineShiyan 430418Hubei ProvinceChina Department of Hepatology The First Hospital of Jilin UniversityChangchun 130031Jilin ProvinceChina Department of Liver Intensive Care Unit Shanghai Public Health Clinical CentreFudan UniversityShanghai 201508China Tianjin Institute of Hepatology Nankai University Second People’s HospitalTianjin 300102China Department of Infectious Diseases and Hepatology The Second Hospital of Shandong UniversityJinan 250033Shandong ProvinceChina Infectious Disease Center The First Affiliated Hospital of Xinjiang Medical UniversityUrumqi 830054XinjiangChina Department of Infectious Diseases Henan Provincial People’s HospitalZhengzhou 450003Henan ProvinceChina Department of Infectious Diseases Hwamei HospitalThe Second Hospital of NingboUniversity of Chinese Academy of SciencesNingbo 315153Zhejiang ProvinceChina Department of Infectious Diseases The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 5

BACKGROUND Autoimmune liver disease(AILD)has been considered a relatively uncommon disease in China,epidemiological data for AILD in patients with cirrhosis and acute decompensation(AD)is *** To investigate the prevalence,outcome and risk factors for AILD in cirrhotic patients complicated with AD in *** We collected data from patients with cirrhosis and AD from two prospective,multicenter cohorts in hepatitis B virus endemic *** were regularly followed up at the end of 28-d,90-d and 365-d,or until death or liver transplantation(LT).The primary outcome in this study was 90-d LTfree ***-on-chronic liver failure(ACLF)was assessed on admission and during 28-d hospitalization,according to the diagnostic criteria of the European Association for the Study of the Liver(EASL).Risk factors for death were analyzed with logistic regression *** In patients with cirrhosis and AD,the overall prevalence of AILD was 9.3%(242/2597).Prevalence of ACLF was significantly lower in AILD cases(14%)than those with all etiology groups with cirrhosis and AD(22.8%)(P<0.001).Among 242 enrolled AILD patients,the prevalence rates of primary biliary cirrhosis(PBC),autoimmune hepatitis(AIH)and PBC-AIH overlap syndrome(PBC/AIH)were 50.8%,28.5%and 12.0%,*** ACLF patients,the proportions of PBC,AIH and PBC/AIH were 41.2%,29.4% and 20.6%.28-d and 90-d mortality were 43.8% and 80.0% in AILD-related *** etiology of AILD had no significant impact on 28-d,90-d or 365-d LTfree mortality in patients with cirrhosis and AD in both univariate and multivariate *** bilirubin(TB),hepatic encephalopathy(HE)and blood urea nitrogen(BUN)were independent risk factors for 90-d LT-free mortality in multivariate *** development of ACLF during hospitalization only independently correlated to TB and international normalized *** AILD was not rare in hospitalized patients with cirrhosis and AD in China,among which PBC was the m

关键词： Prevalence Autoimmune liver disease Cirrhosis and acute decompensation Mortality Acuteon-chronic liver failure